Clindamycin Hydrochloride
NDC 33261-448
Product Information
Clindamycin Hydrochloride is a ANDA-approved product labeled by Aidarex Pharmaceuticals Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a blue product. This product entry covers the primary NDC 33261-448 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
GREEN (C48329 - LIGHT GREEN BODY)
BLUE (C48333 - TURQUOISE BLUE BODY)
22 MM
RX692
RX693
Code Structure Chart
Product Details
What is NDC 33261-448?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W)
- CLINDAMYCIN (UNII: 3U02EL437C) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- STARCH, CORN (UNII: O8232NY3SJ)
- TALC (UNII: 7SEV7J4R1U)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- GELATIN (UNII: 2G86QN327L)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
- D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
- SHELLAC (UNII: 46N107B71O)
- POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197518 - clindamycin HCl 150 MG Oral Capsule
- RxCUI: 197518 - clindamycin 150 MG Oral Capsule
- RxCUI: 197518 - clindamycin (as clindamycin HCl) 150 MG Oral Capsule
- RxCUI: 284215 - clindamycin HCl 300 MG Oral Capsule
- RxCUI: 284215 - clindamycin 300 MG Oral Capsule
* Please review the full disclaimer at the bottom of this page.